The five-year survival rate for pancreatic cancer sits at approximately 13%, among the lowest of any major cancer diagnosis. The disease is typically detected after it has already spread, because it produces few symptoms in its early and most treatable stages. In that context, a new FDA approval for pancreatic cancer is not a routine […]

The post7 facts about the FDA pancreatic cancer drug breakthroughappeared first onRolling Out.